Proteinase inhibitors: a promising drug class for treating leishmaniasis
Bernardo Acacio Santini Pereira, Franklin Souza-Silva, Mariana Silva-Almeida
1Laboratorio de Biologia Molecular e Doenças Endemicas, Instituto Oswaldo Cruz - Fiocruz, Avenida Brasil, 4365 Pavilhao Leonidas Deane, sala 209A, Manguinhos, Rio de Janeiro, RJ - CEP: 21040-900, Brasil. calves@ioc.fiocruz.br.
Abstract:
This review presents and discusses the current status and perspectives of leishmaniasis treatment, with a special focus on the use of proteinase inhibitors. The history of treatment development, the first- and second-choice modern drugs and the advantages and disadvantages of using proteinases inhibitors as leishmanicidal treatments are presented and discussed. The reports gathered herein confirm the potential usefulness of proteinases inhibitors as an alternative or complement to the current leishmaniasis treatments. They also support the hypothesis that a combined treatment with multiple proteinase inhibitors may be efficient against Leishmania infections in vertebrate hosts.
More Related Videos
08:48Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
Published on: January 26, 2016
12:22A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line
Published on: December 30, 2012
Related Concept Videos
Anthelminthic Agents
Inhibitors of Viral Protein Synthesis
